The Drug Safety Research Unit (DSRU) is an independent academic unit internationally respected for its work in Pharmacovigilance, Pharmacoepidemiology, Risk Management and Training Services for over 30 years.
In partnership with doctors in England, the DSRU, led by Director Professor Saad Shakir, aims to protect patients in primary and specialist care from unwanted adverse effects of newly marketed medicines using our unique methods of monitoring patients during the lifecycle of medicines.
The DSRU has recruited new research fellow, Samantha Lane, to start a new project to measure the impact of product withdrawals and other major pharmacovigilance actions on the public health burden since the implementation of the EU PV legislation in 2012. The results will be compared with those of two previous DSRU studies which looked at evidence used to support product withdrawals covering the periods 1999-2001 and 2002-2011.
One of the key priorities of PRAC’s Strategy on Measuring the Impact of Pharmacovigilance Activities (adopted January 2016) was the creation of an ENCePP Special Interest Group (SIG) on Impact, of which DSRU Director, Prof Saad Shakir, is a member. Sam’s project will form the DSRU’s contribution to the ENCePP SIG.
Sam is pictured here (R) with Saad Shakir and Liz Lynn.View our latest news
The Drug Safety Research Unit (DSRU) offers a range of Pharmacovigilance (PV) training courses suitable for those looking for a career in pharmacovigilance, seeking career progression or in a position that requires PV knowledge and understanding. Depending on specific interests and current knowledge, the team at the DSRU is able to recommend which of our training courses could help […]View all our latest questions